Bristol Myers Squibb Co (BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Ticker
BMY
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$128.57B
52-week range
$45.27 - $68.64

Valuation

Share price
$62.93 (close of Nov 16, 2026)
P/E (TTM)
13.89x
Price to book
5.49x
Price to free cash flow
13.85x
Enterprise value
$160.79B
Book value per share
$11.46

Price performance

PeriodChange
1 day-0.79%
5 days+1.27%
1 month+5.32%
3 months-1.41%
6 months+10.40%
Year to date+16.67%
1 year+34.90%
3 years+23.78%
5 years+6.48%
10 years+11.98%
All time+3,271.78%

Short interest

As of
Oct 30, 2026
Short % of float
2.30%
Shares short
46.85M
Days to cover
4.24
Change since prior report
-6.20%
Source
FINRA consolidated short interest

Members of Congress who disclosed BMY trades

Julie Johnson · Gilbert Ray Cisneros · Julia Letlow · Virginia Foxx · Alan Armstrong · Greg Landsman · Jefferson Shreve · Mike Kelly · Tommy Tuberville · Val Hoyle

Super investors holding BMY

Richard Pzena (Pzena Investment Management) · Ken Griffin (Citadel) · John Rogers (Ariel Investments LLC) · Kahn Brothers (Kahn Brothers Group) · Bill Miller (Miller Value Partners, LLC) · Hillman Capital (Hillman Capital Management, Inc) · Dodge & Cox (Dodge & Cox Funds) · Tweedy Browne (Tweedy Browne Company LLC) · Mairs & Power (Mairs & Power Inc)

Profitability and growth

Return on equity
38.12%
Return on invested capital
13.63%*
Return on assets
7.83%
Return on capital employed
16.84%*
Gross margin
71.08%
Net margin
14.64%
EBITDA margin
31.60%
Revenue growth
-0.22%
Free cash flow growth
-7.87%

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash flow and balance sheet

Free cash flow yield (TTM)
7.22%
Current ratio
1.59x
Net debt to EBITDA
2.04x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$48.19B
Cost of revenue
$13.94B
Gross profit
$34.26B
EBITDA
$15.23B
Net income
$7.05B
Earnings per share
$3.47
Research and development
$9.95B
Interest expense
$1.89B
Shares outstanding
2.03B

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$48.19B$34.26B$7.05B$3.47
2024-12-31$48.30B$34.33B-$8.95B-$4.41
2023-12-31$45.01B$34.31B$8.03B$3.88
2022-12-31$46.16B$36.02B$6.33B$2.97
2021-12-31$46.38B$36.45B$6.99B$3.15
2020-12-31$42.52B$30.75B-$9.02B-$3.99
2019-12-31$26.14B$18.07B$3.44B$2.02
2018-12-31$22.56B$16.09B$4.92B$3.01
2017-12-31$20.78B$14.68B$1.01B$0.61
2016-12-31$19.43B$14.48B$4.46B$2.67

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3171.08%14.64%38.12%13.63%*
2024-12-3171.08%-18.53%-54.60%-9.52%*
2023-12-3176.24%17.83%27.22%12.98%*
2022-12-3178.04%13.71%20.33%10.55%*
2021-12-3178.57%15.08%19.42%10.23%*
2020-12-3172.31%-21.20%-23.80%-6.09%*
2019-12-3169.10%13.15%6.65%4.15%*
2018-12-3171.34%21.81%34.83%23.89%*
2017-12-3170.67%4.85%8.50%13.45%*
2016-12-3174.54%22.94%27.26%20.27%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCashDebt
2025-12-31$10.67B$42.85B
2024-12-31$10.86B$47.60B
2023-12-31$12.28B$36.65B
2022-12-31$9.25B$35.06B
2021-12-31$13.98B$39.60B
2020-12-31$14.55B$48.34B
2019-12-31$12.35B$43.39B
2018-12-31$6.91B$5.65B
2017-12-31$5.42B$6.97B
2016-12-31$4.24B$5.72B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$12.85B$553.00M
2024-12-31$13.94B$507.00M
2023-12-31$12.65B$518.00M
2022-12-31$11.95B$457.00M
2021-12-31$15.23B$583.00M
2020-12-31$13.30B$779.00M
2019-12-31$7.37B$441.00M
2018-12-31$6.12B$221.00M
2017-12-31$4.22B$199.00M
2016-12-31$1.84B$205.00M

Dividend history

Most recent payment
Oct 2, 2026
Paid in the last twelve months
$2.52
Payment dateDividend per share
2026-10-02$0.63
2026-07-02$0.63
2026-04-02$0.63
2026-01-02$0.63
2025-10-03$0.62
2025-07-03$0.62
2025-04-04$0.62
2025-01-03$0.62

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-29Sep 2026$1.21
2026-07-30Jun 2026$1.59
2026-04-30Mar 2026$1.44
2026-02-05Dec 2025$1.15
2025-10-30Sep 2025$1.48
2025-07-31Jun 2025$1.07
2025-04-24Mar 2025$1.51
2025-02-06Dec 2024$1.46

Filings and sources

Company website
bms.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Biogen Inc. (BIIB) · Pfizer Inc (PFE) · Organon & Co. (OGN) · Gilead Sciences, Inc. (GILD) · GSK plc (GSK) · Amgen Inc (AMGN) · Novo Nordisk A S (NVO) · AstraZeneca plc (AZN)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades